Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Lantheus Holdings Inc (NASDAQ:LNTH). stock has reached a new 52-week low, touching $72.92. This recent dip marks a significant downturn for the company, which has seen its stock value decrease by 33.18% over the past year. According to InvestingPro analysis, the company maintains strong fundamentals with a "GREAT" financial health score and appears undervalued at current levels. The 52-week low is indicative of the challenges the company has faced, reflecting broader trends and specific company dynamics that have impacted investor confidence. Despite previous periods of growth, Lantheus Holdings Inc. now finds itself navigating a more challenging market environment, as evidenced by this new low point in its stock performance. The company maintains solid fundamentals with a healthy current ratio of 5.74 and revenue growth of 12.53%. For deeper insights and additional analysis, including 8 key ProTips and comprehensive valuation metrics, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Lantheus Holdings reported its Q1 2025 earnings, which fell short of analysts’ expectations. The company’s earnings per share (EPS) came in at $1.53, missing the forecast of $1.64, while revenue reached $372.8 million, below the anticipated $377.79 million. This earnings miss has raised concerns among investors, as reflected in the stock’s decline. Truist Securities adjusted its outlook on Lantheus, reducing the price target from $127 to $117 but maintained a Buy recommendation, citing the company’s growth potential despite the recent setback. The firm highlighted the company’s trading at a lower price-to-earnings ratio and its long-term growth prospects. Lantheus also announced its plans to divest its SPECT business to Shine Technologies, a strategic move aimed at focusing on PET diagnostics and radiotherapeutics. Additionally, Lantheus completed acquisitions of Evergreen Theranostics and Life Molecular Imaging, which are expected to bolster its leadership in radiopharmaceuticals and drive long-term growth. The company provided guidance for 2025, projecting revenue between $1.55 billion and $1.585 billion, with anticipated double-digit revenue growth in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.